Tez (Tıpta Uzmanlık) - Süleyman Demirel Üniversitesi, Tıp Fakültesi, Anesteziyoloji ve Reanimasyon Anabilim Dalı, 2006. / Kaynakça var.

Diss. (sammanfattning) Stockholm : Karol. inst., 2003. / Härtill 5 uppsatser.

Thesis (Ph. D.)--Carleton University, 2005. / Includes bibliographical references (p. 183-193). Also available in electronic format on the Internet.

Stuttgart, Univ., Diss., 2004.

Thesis (Ph. D.)--Oregon State University, 2006. / Printout. Includes bibliographical references. Also available on the World Wide Web.

Estudos prévios mostram que tanto a melatonina (MEL) como a Dehidroepiandrosterona (DHEA) aumentaram a resposta imune contra distintos parasitas. O presente estudo investigou a atividade in vitro da MEL e DHEA associados em um período de 24 horas e in vivo durante o curso da infecção por T. cruzi. A atividade in vitro da MEL e DHEA sozinhos, bem como juntos foram testados sobre formas tripomastigotas (doses variando de 0.5, 8, 20, 32, 40 to 128 µM). In vitro, tanto MEL como DHEA sozinhos não mostraram qualquer atividade contras formas tripomastigotas, embora quando utilizadas em concentrações mais elevadas, a associação de MEL e DHEA mostrou-se ativa contra formas tripomastigotas do parasita. Entretanto, para estas altas concentrações, verificou-se alta toxicidade sobre os macrófagos peritoneais. Para avaliação in vivo, ratos machos Wistar foram infectados com a cepa Y de T. cruzi. Os animais foram oralmente tratados com 5 mg/kg peso corpóreo/dia de MEL e de forma subcutânea com 40mg/kg peso corpóreo/dia de DHEA. Tratamento com MEL, DHEA e associado mostrou uma redução significante no número de tripomastigotas sangüíneos durante a fase aguda da infecção quando comparado aos animais não trados (P<0.05). Um significante aumento no número de macrófagos e concentração de óxido nítrico (NO) foram observados durante o pico da parasitemia apenas com MEL ou combinado com DHEA. Entretanto, observou-se que o DHEA sozinho aumentou a concentração de NO (P<0.05), bem como os níveis de TNF-alfa durante a infecção (P<0.05). Estes resultados mostram que a MEL, DHEA ou a associação de ambos reduz a parasitemia durante a fase aguda de infecção. A ação combinada de ambos os hormônios não exerceu uma ação sinérgica sobre a magnitude da resposta imune do hospedeiro, ficando o DHEA como a substância que induziu a resposta imune mais eficiente. / Previous studies show that melatonin (MEL) and dehydroepiandrosterone (DHEA) enhances the immune response against parasitic pathogens. The present study investigated the in vitro activity of MEL and DHEA association in a period of 24 hours and in vivo during the course of T. cruzi infection. The in vitro activity of MEL and DHEA alone, as well as together, were tested for the trypomastigote forms (doses ranging from 0.5, 8, 20, 32, 40 to 128µM). In vitro, nor MEL nor DHEA alone did not show any activity against trypomastigote forms, although when the highest concentration of MEL and DHEA association was used, it was active against the trypomastigote forms of the parasite. However, for this concentration, a quite toxicity on peritoneal macrophages was observed. For in vivo evaluation, male Wistar rats were infected with the Y strain of T. cruzi. They were orally treated with 5mg/kg body weight/day of MEL and subcutaneously with 40mg/kg body weight/day of DHEA. Treatment with MEL, DHEA and the association showed a significant reduction in the number of blood trypomastigotes during the acute phase of infection as compared to untreated animals (P<0.05). A significant increase in the number of macrophages and nitric oxide (NO) concentrations were observed during the peak of parasitemia with MEL alone or combined with DHEA. However, with DHEA alone, the highest concentration of NO was observed (P<0.05). Moreover, DHEA treatment increased TNF-alpha levels during infection (P<0.05). These results show that MEL, DHEA or the association of both reduces parasitemia during the acute phase of infection. The combined action of both hormones did not exert a synergic action on the hosts ability to fight infection, and it seems that among all treatments DHEA induces a more efficient immune response.

Submitted by LÍVIA CARVALHO FERREIRA null (livinha_ferreira@hotmail.com) on 2017-12-07T17:35:22Z No. of bitstreams: 1 TESE FINAL.pdf: 2973167 bytes, checksum: a3584a471121034b22fc9cfcef852a73 (MD5) / Approved for entry into archive by Elza Mitiko Sato null (elzasato@ibilce.unesp.br) on 2017-12-07T18:59:29Z (GMT) No. of bitstreams: 1 ferreira_lc_dr_sjrp.pdf: 2973167 bytes, checksum: a3584a471121034b22fc9cfcef852a73 (MD5) / Made available in DSpace on 2017-12-07T18:59:29Z (GMT). No. of bitstreams: 1 ferreira_lc_dr_sjrp.pdf: 2973167 bytes, checksum: a3584a471121034b22fc9cfcef852a73 (MD5) Previous issue date: 2017-11-10 / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / O câncer de mama apresenta altas taxas de incidência e também de mortalidade, sendo a neoplasia mais comum entre as mulheres. MicroRNAs (miRNAs) são pequenas moléculas de RNAs não codificantes que desempenham papel fundamental na regulação gênica. Estudos recentes têm demonstrado que miRNAs estão diretamente envolvidos na iniciação e progressão de vários tipos tumorais, incluindo o câncer de mama. Diversos miRNAs têm sido descritos como promotores ou supressores tumorais, podendo estar associados ao crescimento do tumor e metástase. Atualmente, tem sido demonstrado que a administração exógena da melatonina, um hormônio naturalmente secretado pela glândula pineal, apresenta diversos efeitos oncostáticos em diferentes tipos tumorais. Assim, o objetivo do presente estudo foi avaliar o papel da melatonina em uma possível via metastática envolvendo a regulação de miRNAs em células da linhagem de câncer de mama metastática e triplo-negativa MDA-MB-231. Inicialmente, a expressão de 384 miRNAs foi avaliada utilizando placas “Taqman Low-density Array” (TLDA). Para futuras validações, foram selecionados apenas miRNAs que apresentaram fold change >1,5 e <0,5. Os resultados demonstraram que a melatonina modulou a expressão de 17 miRNAs (11 superexpressos e 6 inibidos). Dentre os miRNAs modulados pela melatonina, miR-148b e miR-210 foram confirmados por qRT-PCR, selecionados e utilizados para investigações funcionais. As células MDAMB-231 foram então transfectadas para inibição de miR-148b e/ou miR-210 (permanente ou transiente, respectivamente), e avaliadas após tratamento com melatonina. Em seguida foram avaliadas a taxa de migração e expressão proteica de cMyc, possível gene alvo de miR-148b e miR-210. Os resultados demonstraram que a melatonina foi capaz de reduzir a expressão de c-Myc e afetar a taxa de migração das células modificadas ou não com miR-148b. No entanto, nenhum efeito sobre c-Myc ou migração foi observado em células modificadas para miR-148b, quando comparadas as células controle. No que se refere ao miR-210, a melatonina alterou a expressão de cMyc e migração celular, nas células tratadas com melatonina ou expressando anti-miR210. Em resumo, nossos resultados demonstraram que apesar da melatonina influenciar na modulação positiva do miR-148b e miR-210 em células tumorais de mama triplonegativas, esta regulação não foi necessariamente causativa para alterar a expressão de c-Myc ou diminuir a taxa de migração destas células. Nossos resultados confirmam o efeito da melatonina na inibição da proliferação e migração celular, especialmente em células triplo-negativas, sugerindo seu importante papel no controle da progressão tumoral. No entanto, ainda é necessário estabelecer uma ligação direta entre as modulações de certas proteínas ou miRNAs com os efeitos da melatonina. / Breast cancer has high rates of incidence and mortality, and it is the most common cancer among women. MicroRNAs (miRNAs) are small molecules of non-coding mRNA that play a key role in gene regulation. Recent studies have shown that miRNAs are directly involved in the initiation and progression of various tumor types, including breast cancer. Several miRNAs have been described as promoters or suppressors of metastasis and may be associated with tumor growth and metastasis. Exogenous administration of melatonin, a hormone secreted by the pineal gland, has been shown several oncostatics effects on different types of cancers. Herein, we investigated if the antimetastatic effects of melatonin were coordinated by miRNAs involved in tumor progression. The expression of 384 miRNAs was measured using Taqman Low-density Array (TLDA) cards. Considering the cut-off we imposed (fold change >1.5 and (fold change >1.5 and<0.5) were evidenced the modulation of 17 miRNAs (11 up and 6 down). Among all miRNAs modulated, the selected miR-210 and miR-148b were further confirmed by qRT-PCR and tested for functional investigations. First, we engineered cells for miR-210 or miR-148b overexpression or depletion (stable or transient), then we evaluated the effect of melatonin on c-Myc protein expression and migration. Melatonin reduced c-Myc expression and migration in cell depleted or not for miR-148b. However no effect on c-Myc or migration was observed for cells depleted for miR-148b when compared with control cells. c-Myc and migration were reduced in cells treated with melatonin or expressing anti-miR-210 (depleted). In summary, our results suggest that, even if melatonin alters miRNA expression, the modulations of the miRNAs we studied, miR-210 and miR-148b, are not essential for melatonin inhibition of cell migration and c-Myc expression. One of the hypotheses is that c-Myc is not a target of these miRNAs in MDA-MB-231 cells, and it is believed that melatonin effects on miRNAs could be just “epiphenomenon” due to general Dicer/Drosha deregulations. Nevertheless, melatonin remains a powerful molecule for metastatic traits inhibition, which modulates a set of protein-coding genes, such as c-Myc. However, a direct link between expression modulations of certain proteins or miRNAs and melatonin effects has still to be established. / 2013/24612-5

La mélatonine est une hormone synthétisée et sécrétée uniquement la nuit par la glande pinéale. Son rôle principal est son implication dans la synchronisation de la saison de reproduction. La mélatonine se lie aux récepteurs, MT1 et MT,, membres de la famille des récepteurs à sept domaines transmembranaires couplés aux protéines G (RCPG).Le clonage récent du récepteur ovin MT2a remis en cause toutes les données connues. La pharmacologie et les voies de signalisation du récepteur oMT2ont été étudiées et sont communes à celles des récepteurs des autres espèces. En revanche, oMT2possède une originalité de séquence avec la présence du motif DRY, fortement impliqué dans l’établissement de l’activité constitutive des RCPG. D’une part, nous avons montré que l’ensemble des récepteurs MT possèdent une activité constitutive. D’autre part, nous avons identifié deux agonistes inverses pour les récepteurs hMT2, initialement décrits comme antagonistes. Dans l’optique de discriminer les rôles respectifs des récepteurs MT in vivo, le développement d’une approche par ARN interférents a été validée dans un modèle cellulaire, la lignée CHO-KI exprimant les récepteurs ovins et de rat. / Melatonin is a hormone synthesized and secreted only during night by pineal gland. A main role of melatoninconcerns its implication in the synchronization of reproductive seasonality. Binding sites of melatonin are MT1and MT2 receptors which belong to the superfamily of seven-transmembrane-spanning G protein-coupledreceptors (GPCRs).Recent cloning of ovine MT2 receptor has challenged the knowledge about melatonin receptors. Wedemonstrated that its pharmacology and signalling pathways were similar to subtype 2 receptor of othersspecies (human and rat). Nevertheless, oMT2 receptor possesses a particularity of sequence, with the presenceof DRY motif which is known to be involved in the establishment of constitutive activity of GPCRs. In ourstudy, we demonstrated the existence of constitutive activity for ail the melatonin receptors. In addition, weidentified two inverse agonists for human MT2 receptors, previously described as antagonists. To describe therespective roles of each subtype of melatonin receptors in vivo, siRNA approach was developed in cell line,CI-10-K Iexpressing ovine and rat melatonin receptors

The physiological and behavioral functions of the body are coordinated into daily patterns that are synchronized with the earth's light/dark cycles. This patterning of function is referred to as circadian rhythms. A central pacemaker located in suprachiasmatic nucleus of the brain serves to coordinate the body's rhythms with the light/dark cycle. Disturbances in normal circadian rhythm have been shown to increase the risk of certain types of cancer, including breast cancer. This effect is so significant that the World Health Organization has recently classified shift work as a probable carcinogen. One effect of alteration in the light/dark cycle such as that experienced by shift workers is a change in the production of the pineal hormone melatonin (N-acetyl-5-methoxytryptamine). Secretion of melatonin is regulated by the suprachiasmatic nucleus. Melatonin has a wide variety of functions including physiological regulation of sleep, modulation of the immune system and antioxidant action. Recent studies have determined that melatonin has oncostatic actions in a variety of cancers, including breast, prostate and endometrial cancer. Thus, this thesis explores the effects of melatonin on clock gene expression and growth of a mouse mammary tumor cell line, EMT6. I hypothesized that growth inhibitory actions of melatonin involve alteration in clock gene expression, induction of apoptosis and cell cycle arrest. Thus, this thesis investigates the modulatory effects of melatonin on clock genes, cell cycle parameters and apoptosis. Western blot analysis and immunocytochemistry confirmed expression of melatonin receptors in the EMT6 cell line. I investigated the circadian rhythm of EMT6 cells by measuring the clock gene expression pattern over a 24 hour period. I found a significant rhythm in Per1 and Per2 transcripts. Expression of estrogen and progesterone receptors was measured as they are putative clock controlled genes involved in the development of breast cancer. The results showed significant rhythm in Per1 (p=0.05), Per2 (p=0.03) and estrogen receptors ERalpha (p=0.001) and ERbeta (p=0.028). Peak expression for Period genes and ERalpha is found at 16 hrs and 20 hrs after serum shock, respectively. Peak expression for ERbeta is found at 24 hours after serum shock. Other steroid hormone receptors such as progesterone receptors PRB and PRA+B were not rhythmic. Treatment with melatonin in a concentration range from 10µM to 1nM inhibited growth in the cells. The antiproliferative effect of melatonin was dose and time dependent. At the end of 48 hours, melatonin at a concentration of 10-7 M induced apoptosis in EMT6 cells as indicated by caspase-3 immunocytochemistry. Furthermore, this same treatment caused an upregulation of the clock gene and putative tumor suppressor gene, Per2. These studies provide evidence that melatonin alters growth of EMT6 cells by inducing caspase-3 and apoptosis, which may be regulated through induction of Per2. Thus, disturbance in rhythmic secretion of melatonin may promote tumor progression in breast cancer.

Among all of the devastating effects that Parkinson’s disease (PD) has on an individual, sleep dysfunction is one that can have a profound effect on the entire family of the patient. The most potentially destructive of these sleep syndromes being that of Rapid Eye Movement Sleep Behavior Disorder (RBD). This disorder not only causes sleep impairment to the patient, but can occasionally result in life-threatening injury to the individual or their bed partner. While this condition is manageable with medication, the current treatment of choice is a long-acting benzodiazepine, clonazepam. This drug, while effective in treating RBD, comes with a significant burden of side effects. Patients with neurodegenerative disorders, like PD, are at even higher risk of suffering the negative impacts of this treatment. One potential alternative treatment that has been considered is a supplement of exogenous melatonin, a hormone that plays a role in maintaining one’s circadian rhythm. Several small case studies have shown potential efficacy of this treatment, and with very few side effects. However, this efficacy has not yet been proven by randomized clinical trial. This proposed study will perform a double-blind randomized clinical trial of melatonin vs. placebo in a population of PD patients with RBD. Subjects will be analyzed via polysomnographic sleep study, where symptoms will be scored on the RBD Severity Scale (RBDSS) at baseline and after a treatment intervention. Statistical analysis will then ascertain whether or not a significant symptom reduction is seen following melatonin treatment, compared to a group receiving placebo. If melatonin proves to be efficacious in this patient population, this would give clinicians a new treatment option to consider to effectively manage symptoms of RBD with a much lower risk of potentially harmful side effects. Finding an effective method of managing this condition, the prevalence of which continues to rise worldwide, will have a great impact on improving the safety and quality of life of these patients.